Actively Recruiting
Study on Plasmablastic Lymphoma Patients
Led by Fondazione Italiana Linfomi - ETS · Updated on 2025-12-02
200
Participants Needed
23
Research Sites
154 weeks
Total Duration
On this page
Sponsors
F
Fondazione Italiana Linfomi - ETS
Lead Sponsor
A
AIL Roma - Italia
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.
CONDITIONS
Official Title
Study on Plasmablastic Lymphoma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022
- Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
- Age > 18 years old
- Availability of complete medical records
- Availability of histopathological material requested by the study
You will not qualify if you...
- Any other histology than PBL
- Lack of complete medical records
- Lack of histopathological material requested by the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 23 locations
1
IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati
Aviano, PN, Italy
Actively Recruiting
2
Ospedale C.e G. Mazzoni, U.O.C. di Ematologia
Ascoli Piceno, Italy
Actively Recruiting
3
ASST Spedali Civili di Brescia, Ematologia
Brescia, Italy
Not Yet Recruiting
4
A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo
Cuneo, Italy
Actively Recruiting
5
Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia
Florence, Italy
Actively Recruiting
6
ASST -Fatebenefratelli - Polo Luigi Sacco Oncologia
Milan, Italy
Not Yet Recruiting
7
ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia
Milan, Italy
Actively Recruiting
8
Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
Milan, Italy
Actively Recruiting
9
Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia
Milan, Italy
Not Yet Recruiting
10
Fondazione IRCCS San Gerardo dei Tintori, Ematologia
Monza, Italy
Actively Recruiting
11
AOU Maggiore della Caritа di Novara, SCDU Ematologia
Novara, Italy
Actively Recruiting
12
Azienda Ospedaliera Universitaria di Padova, Ematologia
Padova, Italy
Not Yet Recruiting
13
Presidio ospedaliero A. Tortora, U.O. Onco-ematologia
Pagani, Italy
Not Yet Recruiting
14
Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia
Reggio Emilia, Italy
Actively Recruiting
15
Azienda Ospedaliera Universitaria Sant' Andrea, Ematologia
Roma, Italy
Actively Recruiting
16
Policlinico Umberto I - Università La Sapienza, Istituto Ematologia, Dipartimento di Medicina Traslazionale e di Precisione
Roma, Italy
Actively Recruiting
17
Universitа Cattolica S. Cuore, Ematologia
Roma, Italy
Not Yet Recruiting
18
Azienda Ospedaliero Universitaria Senese, U.O.C. Ematologia
Siena, Italy
Not Yet Recruiting
19
A.O.U. Città della Salute e della Scienza di Torino, Ematologia Universitaria
Torino, Italy
Not Yet Recruiting
20
A.O.U. Città della Salute e della Scienza di Torino, S.C. Ematologia
Torino, Italy
Not Yet Recruiting
21
Ospedale S. Chiara, S.S. di Ematologia
Trento, Italy
Actively Recruiting
22
ULSS2 Marca Trevigiana, Ospedale Ca' Foncello, S.C di Ematologia
Treviso, Italy
Not Yet Recruiting
23
ULSS 8 Berica - Ospedale S. Bortolo, Ematologia
Vicenza, Italy
Actively Recruiting
Research Team
U
Uffici Studi FIL
CONTACT
U
Uffici Studi FIL
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here